ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1990

Risk of Falling Is Equivalent Between Patients with Rheumatoid Arthritis and Healthy Individuals – the Tomorrow Study-

Kenji Mamoto1, Tatsuya Koike2, Tadashi Okano1, Atsuko Kamiyama2, Yuko Sugioka1, Masahiro Tada1 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA), risk assessment and study design

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falling. The present study prospectively determines the incidence of falls and their risk factors in patients with RA who participated in the TOMORROW (TOtal Management Of Risk factors in Rheumatoid arthritis patients to lOW er morbidity and mortality; clinical trial registration number: UMIN000003876) study that was started in 2010.

Methods: We evaluated anthropometric parameters, muscle volume, bone mineral density (BMD), disease activity, general health status and the occurrence of falls for a period of two years in 202 patients with RA ( mean age: 58.4 years, 54% administered with biological agents) and 202 age- and sex-matched healthy volunteers (HV, mean age: 57.4 years).

Results:  Among the patients with RA and HV, 29.6% and 26.7% respectively reported one or more falls during two years. These values did not significantly differ in the two groups. The fall group had higher age, lower BMD (p<0.01), higher whole % Fat mass (p<0.01) and tended to have induced walking time. After adjusting for risk factors of falls such as age, gender, smoking and BMI, multiple logistic regression analysis identified that a history of falls was the most significant parameter associated with falls (odds ratio: 2.39, p=0.001) (Table 1). The RA group also had lower whole muscle volume (37.2 vs. 39.6 kg; p = 0.001), leg BMD (0.967 vs. 1.031 mg/cm3; p < 0.001) and shorter exercise periods than HV, but none of these were associated with rates of falling. Furthermore, fall risk did not significantly and linearly increase with disease duration, disease activity score and physical status among the patients with RA.

Conclusion:

We concluded that the fall rate is not higher in patients with RA than in healthy volunteers and that only a history of falls plays a role in increasing the risk of falls.


Disclosure:

K. Mamoto,
None;

T. Koike,

Chugai Pharmaceutical,

2,

Eli Lilly Japan,

8,

Novartis Pharmaceutical Corporation,

2,

Teijin Pharma,

8,

Bristol-Myers Squibb,

5,

Ono Pharmaceutical,

8,

Santen Pharmaceutical,

8,

Eisai,

8,

Abbott Japan,

8,

Mitsubishi Tanabe Pharma Corporation,

2,

Takeda Pharmaceutical,

8,

Astellas Pharma Inc.,

8,

Pfizer Japan Inc.,

8,

Janssen Pharmaceutical,

2,

Asahi Kasei Pharma Corporation,

8,

Daiichi Sankyo Company,

2;

T. Okano,
None;

A. Kamiyama,
None;

Y. Sugioka,
None;

M. Tada,
None;

H. Nakamura,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-falling-is-equivalent-between-patients-with-rheumatoid-arthritis-and-healthy-individuals-the-tomorrow-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology